Our global pharmaceuticals and life sciences team provides a range of innovative pharmaceutical, biotechnology, and medical device companies with market-leading legal knowledge and a highly commercial approach to doing business in this dynamic sector. With capabilities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia, we can provide integrated advice on both domestic and cross-border matters for our pharmaceutical and technology clients.
Our clients include innovative pharmaceutical companies, bioscience and biotechnology companies, medical device manufacturers and food technology companies and their investors, including venture capital and private equity firms. Many of our lawyers have scientific backgrounds and a deep industry focus, enabling us to advise on all aspects of the pharmaceutical life cycle – from innovation, development, commercialisation and exploitation, through to contentious proceedings before the courts and regulatory authorities.
Our areas of work include
- international IP litigation
- product liability
- IP strategies
- fund raising and investment
- regulatory and compliance
- labour and employment
- government investigations.
Our recent work
- A combined team from the Toronto, Ottawa, Montreal, Sydney and Melbourne offices advised Bioniche, a Canadian biopharmaceutical company on its loan arrangements.
- Acting for numerous innovator clients regarding patent infringement actions in Canada including Pfizer, Eli Lilly, Merck, Servier and Gilead.
- Advising on the Dutch law aspects of financing Advent International’s public offer for the entire share capital of Mediq NV, a Dutch-listed international provider of medical devices, pharmaceuticals and associated services.
- Representing a major US pharmaceutical company in four separate class actions in Canada as part of a global team of lawyers defending product liability claims.
- Effectively representing Sanofi in its dispute with Sepal Pharma in the French Court of Appeal.
- Advising Australian ASK-listed company Virax Holdings Limited on its Licensing Agreement with the French biopharmaceutical Company Transgene S.A.